絞り込み

17061

広告

「elotuzumab」の検索結果

274件中 61件~80件表示    検索結果をPubMedで見る PubMedで見る

2B4 (CD244, SLAMF4) and CS1 (CD319, SLAMF7) in systemic lupus erythematosus and cancer.

Elotuzumab in Combination with Lenalidomide and Dexamethasone for Treatment-resistant Immunoglobulin Light Chain Amyloidosis With Multiple Myeloma.

Therapeutic antibodies for multiple myeloma.

[Immunopathogenesis and appropriate use of monoclonal antibody agents in multiple myeloma].

Response to therapeutic monoclonal antibodies for multiple myeloma in African Americans versus whites.

Elotuzumab: A Review in Relapsed and/or Refractory Multiple Myeloma.

Practical Considerations for Antibodies in Myeloma.

Elotuzumab Plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 4-Year Follow-Up and Analysis of Relative Progression-Free Survival From the Randomized ELOQUENT-2 Trial.

Therapeutic Monoclonal Antibodies and the Value of the Free Light Chain Assay in Myeloma.

Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study.

Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.

Carfilzomib.

Pomalidomide.

The Multiple Myeloma Drug Pipeline-2018: A Review of Small Molecules and Their Therapeutic Targets.

Managing Infusion Reactions to New Monoclonal Antibodies in Multiple Myeloma: Daratumumab and Elotuzumab.

Monoclonal Antibodies for Myeloma: Make It Easy!

Maintenance and continuous therapy for multiple myeloma.

Interference of Therapeutic Monoclonal Antibodies With Routine Serum Protein Electrophoresis and Immunofixation in Patients With Myeloma: Frequency and Duration of Detection of Daratumumab and Elotuzumab.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
Sort by
※並べ替えは表示に時間がかかります